NZ Lung Cancer Research Review Issue 16

In this issue:
  -  KEYNOTE-189: patient-reported outcomes
  -  Chemoimmunotherapy for stage IIIA disease
  -  Brigatinib vs crizotinib in ALK+ disease
  -  1L immunotherapy ± chemotherapy
  -  Osimertinib and leptomeningeal metastases
  -  Adjuvant chemotherapy and survival
  -  Prognostic value of PET parameters in SCLC
  -  Citrus fruit intake and lung cancer risk
  -  Chr15q25 genetic variant and lung disease risk
  -  Predicting lung cancer with an algorithm

Please login below to download this issue (PDF)

Subscribe